One retrospective study suggested that a higher proportion of advanced mutated-EGFR NSCLC patients died of CNS metastases than did WT-EGFR patients (44.8% vs. 8.3%, P < 0.001) [31]. Here, EGFR is linked to non-small cell lung carcinoma.